@ARTICLE{10.3389/fncel.2020.631802, AUTHOR={Perrier, Stefanie and Michell-Robinson, Mackenzie A. and Bernard, Geneviève}, TITLE={POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches}, JOURNAL={Frontiers in Cellular Neuroscience}, VOLUME={14}, YEAR={2021}, URL={https://www.frontiersin.org/articles/10.3389/fncel.2020.631802}, DOI={10.3389/fncel.2020.631802}, ISSN={1662-5102}, ABSTRACT={Leukodystrophies are a class of rare inherited central nervous system (CNS) disorders that affect the white matter of the brain, typically leading to progressive neurodegeneration and early death. Hypomyelinating leukodystrophies are characterized by the abnormal formation of the myelin sheath during development. POLR3-related or 4H (hypomyelination, hypodontia, and hypogonadotropic hypogonadism) leukodystrophy is one of the most common types of hypomyelinating leukodystrophy for which no curative treatment or disease-modifying therapy is available. This review aims to describe potential therapies that could be further studied for effectiveness in pre-clinical studies, for an eventual translation to the clinic to treat the neurological manifestations associated with POLR3-related leukodystrophy. Here, we discuss the therapeutic approaches that have shown promise in other leukodystrophies, as well as other genetic diseases, and consider their use in treating POLR3-related leukodystrophy. More specifically, we explore the approaches of using stem cell transplantation, gene replacement therapy, and gene editing as potential treatment options, and discuss their possible benefits and limitations as future therapeutic directions.} }